Finansijska isplativost alternativa transfuziji krvi
Hematologija
Early intravenous iron administration in the Emergency Department reduces red blood cell unit transfusion, hospitalisation, re-transfusion, length of stay and costs. (otvara novi prozor)
Izvor: Blood Transfus 2020;18(2):106-16.
Indeks: PubMed 31855149
DOI: 10.2450/2019.0248-19
https://www.ncbi.nlm.nih.gov/pubmed/31855149 (otvara novi prozor)
Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. (otvara novi prozor)
Izvor: Support Care Cancer 2013;21(2):485-93.
Indeks: PubMed 22825456
DOI: 10.1007/s00520-012-1538-0
https://www.ncbi.nlm.nih.gov/pubmed/22825456 (otvara novi prozor)
Restrictive blood transfusion practices are associated with improved patient outcomes. (otvara novi prozor)
Izvor: Transfusion 2014;54(10 Pt 2):2753-9.
Indeks: PubMed 24995770
DOI: 10.1111/trf.12723
https://www.ncbi.nlm.nih.gov/pubmed/24995770 (otvara novi prozor)
Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United Kingdom. (otvara novi prozor)
Izvor: Clin Ther 2010;32(14):2478-93.
Indeks: PubMed 21353116
DOI: 10.1016/j.clinthera.2011.01.011
https://www.ncbi.nlm.nih.gov/pubmed/21353116 (otvara novi prozor)
Recombinant activated factor VII use in critically ill infants with active hemorrhage. (otvara novi prozor)
Izvor: J Pediatr Surg 2008;43(12):2235-8.
Indeks: PubMed 19040942
DOI: 10.1016/j.jpedsurg.2008.08.053
https://www.ncbi.nlm.nih.gov/pubmed/19040942 (otvara novi prozor)
Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. (otvara novi prozor)
Izvor: Blood Adv. 2022;6(3):785-92.
Indeks: PubMed 34781363
DOI: 10.1182/bloodadvances.2021005627
https://pubmed.ncbi.nlm.nih.gov/34781363/ (otvara novi prozor)
Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system-wide patient blood management program. (otvara novi prozor)
Izvor: Transfusion 2017;57(9):2189-96.
Indeks: PubMed 28671296
DOI: 10.1111/trf.14191
https://www.ncbi.nlm.nih.gov/pubmed/28671296 (otvara novi prozor)
Impact of a conservative red blood cell transfusion strategy in children undergoing hematopoietic stem cell transplantation. (otvara novi prozor)
Izvor: Biol Blood Marrow Transplant 2012;18(5):813-7.
Indeks: PubMed 22080050
DOI: 10.1016/j.bbmt.2011.10.043
https://www.ncbi.nlm.nih.gov/pubmed/22080050 (otvara novi prozor)
The cost of blood: a study of the total cost of red blood cell transfusion in patients with β-thalassemia using time-driven activity-based costing. (otvara novi prozor)
Izvor: Transfusion 2019;59(11):3386-95.
Indeks: PubMed 31664712
DOI: 10.1111/trf.15558
https://www.ncbi.nlm.nih.gov/pubmed/31664712 (otvara novi prozor)
Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (otvara novi prozor)
Izvor: Transfusion 2015;55(12):2807-15.
Indeks: PubMed 26264557
DOI: 10.1111/trf.13260
https://www.ncbi.nlm.nih.gov/pubmed/26264557 (otvara novi prozor)
Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (otvara novi prozor)
Izvor: Cancer 2013;119(1):107-14.
Indeks: PubMed 22744794
DOI: 10.1002/cncr.27686
https://www.ncbi.nlm.nih.gov/pubmed/22744794 (otvara novi prozor)
Budget impact analysis on erythropoiesis-stimulating agents use for the management of chemotherapy-induced anaemia in Greece. (otvara novi prozor)
Izvor: Cost Eff Resour Alloc 2013;11(1):16.
Indeks: PubMed 23870502
DOI: 10.1186/1478-7547-11-16
https://www.ncbi.nlm.nih.gov/pubmed/23870502 (otvara novi prozor)
Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (otvara novi prozor)
Izvor: Support Care Cancer 2012;20(1):159-65.
Indeks: PubMed 21359879
DOI: 10.1007/s00520-010-1083-7
https://www.ncbi.nlm.nih.gov/pubmed/21359879 (otvara novi prozor)
Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada. (otvara novi prozor)
Izvor: J Med Econ 2013;16(2):318-26.
Indeks: PubMed 23216012
DOI: 10.3111/13696998.2012.756400
https://www.ncbi.nlm.nih.gov/pubmed/23216012 (otvara novi prozor)
Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study. (otvara novi prozor)
Izvor: Hematology 2018;23(7):417-22.
Indeks: PubMed 29157136
DOI: 10.1080/10245332.2017.1404262
https://www.ncbi.nlm.nih.gov/pubmed/29157136 (otvara novi prozor)
The burden of blood transfusion: a utilization and economic analysis--a pilot study in patients with chemotherapy-induced anemia (CIA). (otvara novi prozor)
Izvor: J Med Econ 2013;16(5):633-8.
Indeks: PubMed 23425291
DOI: 10.3111/13696998.2013.778269
https://www.ncbi.nlm.nih.gov/pubmed/23425291 (otvara novi prozor)
Prospective monitoring of plasma and platelet transfusions in a large teaching hospital results in significant cost reduction. (otvara novi prozor)
Izvor: Transfusion 2010;50(2):487-92.
Indeks: PubMed 19804569
DOI: 10.1111/j.1537-2995.2009.02413.x
https://www.ncbi.nlm.nih.gov/pubmed/19804569 (otvara novi prozor)
Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. (otvara novi prozor)
Izvor: Am J Hematol 2010;85(10):795-7.
Indeks: PubMed 20645429
DOI: 10.1002/ajh.21772
https://www.ncbi.nlm.nih.gov/pubmed/20645429 (otvara novi prozor)
Increased hospital costs associated with red blood cell transfusion. (otvara novi prozor)
Izvor: Transfusion 2015;55(5):1082-9.
Indeks: PubMed 25488623
DOI: 10.1111/trf.12958
https://www.ncbi.nlm.nih.gov/pubmed/25488623 (otvara novi prozor)